MDR-001

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab

Human trial1

Outcomes

Alanine aminotransferase

downin humans1

1 study

MDR-001 decreases alanine aminotransferase in humans (P<.01).
“reduction in WC, BMI, FPG, and ALT were significantly greater with all MDR-001 doses vs PBO (all P<.01)”
Human trial24 weeks
MDR-001, an AI-Enabled β-arrestin2-Biased Oral GLP-1RA: Efficacy and Safety in Chinese Adults with Overweight or Obesity
ADA Scientific Sessions 2026 abstract5 Jun 2026

Latest

1 in 12 months

ADA Scientific Sessions 2026 Abstract5 Jun

MDR-001, an AI-Enabled β-arrestin2-Biased Oral GLP-1RA: Efficacy and Safety in Chinese Adults with Overweight or Obesity

Randomised trial in 317 peopleOverweight

Paper

MDR-001

Outcomes

Latest

MDR-001, an AI-Enabled β-arrestin2-Biased Oral GLP-1RA: Efficacy and Safety in Chinese Adults with Overweight or Obesity

Related